Athersys, Inc., based in Cleveland, Ohio, is a leading biotechnology company specializing in regenerative medicine. Founded in 1995, the company is best known for its innovative MultiStem® platform, an off-the-shelf stem-cell-based therapy designed to enhance tissue repair and regulate immune responses. MultiStem’s unique approach allows scalable production and eliminates the need for donor-recipient matching, making it accessible for a broad range of patients. Athersys is targeting critical unmet medical needs in areas like ischemic stroke, acute respiratory distress syndrome (ARDS), and graft-versus-host disease (GvHD), where conventional treatments often fall short.

The company is advancing MultiStem through rigorous clinical trials, including late-stage studies, while leveraging strategic global collaborations to expedite development. Notably, its work in Japan under the Sakigake Designation aims to accelerate approval for transformative therapies. With a commitment to addressing life-threatening conditions and improving patient outcomes, Athersys is poised to redefine how regenerative medicine is applied in modern healthcare.